Talphera (TLPH) EBITDA Margin (2011 - 2025)

Talphera (TLPH) posted EBITDA Margin of 342200.0% for Q3 2025, down 3068.52% on a QoQ basis from 10800.0% in Q1 2025.

Analysis

Talphera (TLPH) EBITDA Margin (2011 - 2025) Analysis & Trends

Talphera has reported EBITDA Margin for 14 years, with the latest figure at 342200.0% in Q3 2025.

On a quarterly basis, EBITDA Margin changed N/A year-over-year to 342200.0% in Q3 2025; TTM through Jun 2026 was 1474700.0%, a 142524074.0% decrease from a year earlier, with the FY2025 full-year figure at 48157.14%, changed N/A from the prior year.
EBITDA Margin was 342200.0% for Q3 2025 at Talphera, down from 10800.0% in the prior quarter.
The five-year high for EBITDA Margin was 463.64% in Q3 2021, with the low at 408750.0% in Q4 2021.
Average EBITDA Margin over 4 years is 77421.97%, with a median of 2147.9% recorded in 2022.
The largest YoY upside for EBITDA Margin was 231666 bps in 2021 against a maximum downside of 40749743 bps in 2021.
Over 4 years, EBITDA Margin stood at 408750.0% in 2021, then jumped by 100 bps to 2035.07% in 2022, then grew by 25 bps to 1524.2% in 2023, then sank by 22351 bps to 342200.0% in 2025.
The last three EBITDA Margin figures came in at 342200.0% (Q3 2025), 10800.0% (Q1 2025), and 1524.2% (Q4 2023), per Business Quant data.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Amgen	206.44 Bn	192.45 Bn	7.24 Bn	34.95%
2	Gilead Sciences	179.97 Bn	176.79 Bn	6.22 Bn	-133.21%
3	Vertex Pharmaceuticals	130.57 Bn	122.72 Bn	2.84 Bn	37.40%
4	Regeneron Pharmaceuticals	81.63 Bn	73.63 Bn	3.93 Bn	30.15%
5	Argenx Se	60.34 Bn	55.16 Bn	1.37 Bn	32.54%
6	Moderna	54.37 Bn	49.23 Bn	52.00 Mn	-562.07%
7	Alnylam Pharmaceuticals	33.07 Bn	29.76 Bn	992.69 Mn	17.93%
8	Biogen	31.84 Bn	30.55 Bn	1.96 Bn	-23.56%
9	Roivant Sciences	29.49 Bn	29.49 Bn	1.16 Mn	-25,380.93%
10	Talphera	92.90 Mn	92.90 Mn	-	-

Historic Data

Download Data